Shares of Sanofi (SNY) Rally 2.03%

Sanofi (SNY) : Traders are bullish on Sanofi (SNY) as it has outperformed the S&P 500 by a wide margin of 4.11% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.53%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.03% in the last 1 week, and is up 8.65% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 2.6% and the 50-Day Moving Average is 3.62%.

Sanofi (NYSE:SNY): The stock opened at $41.87 on Friday but the bulls could not build on the opening and the stock topped out at $41.93 for the day. The stock traded down to $41.60 during the day, due to lack of any buying support eventually closed down at $41.68 with a loss of -0.69% for the day. The stock had closed at $41.97 on the previous day. The total traded volume was 3,319,205 shares.


The company Insiders own 1% of Sanofi shares according to the proxy statements. Institutional Investors own 9.13% of Sanofi shares.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Companys principal activities. Under the Companys Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.